Amikacin exposure in MDR-TB patients in Uganda: Revisiting old drugs in a new era of resistance – A pharmacokinetic assessment
This population-PK study shows that major differences in PK between Ugandan MDR-TB patients and those in the Global North are unlikely. Our findings reinforce the suitability of a one-compartment model for therapeutic drug monitoring in both high- and low-resource settings. Readily obtained aminoglycoside PK parameters in a limited resource setting facilitate future efforts in optimizing drug exposure with minimal toxicities, in the population most affected by the pandemic of TB.
Authors
- Alexander Jetter (ORCID: https://orcid.org/0000-0002-7394-2192)
- Allan Buzibye (ORCID: https://orcid.org/0000-0001-5874-3219)
- Jan Hongler (ORCID: https://orcid.org/0000-0003-0844-4231)
- Marisa Kälin (ORCID: https://orcid.org/0000-0002-4924-9099)
- Christine Sekaggya-Wiltshire
- Sabine Haller
- Akello Susan Adakun
- Jan Fehr
- Nina Lutz
- Barbara Castelnuovo
Institutions
- Swiss Tropical and Public Health Institute (CH)
- University of Zurich (CH)
- University of St.Gallen (CH)
- Mulago Hospital (UG)
- University Hospital of Zurich (CH)
- Infectious Diseases Institute (UG)
- Makerere University (UG)
Publication Details
- Journal
- New Microbes and New Infections
- Published
- 2026-02-27
- DOI
- https://doi.org/10.1016/j.nmni.2026.101734
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00